RxDoctor Payments Data

Amanda Billingsley, APRN

Family · Pocahontas, ARNPI 1679926141

Payments from drug & device makers

$520in general payments, 2019–2025

Across 34 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$279
  • Boehringer Ingelheim$126
  • AstraZeneca$43
  • Sanofi Pasteur Inc.$17
  • Scynexis, Inc.$17
  • Novo Nordisk$14
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$45387%
  • Education$6713%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$520 in reported general payments places this provider in the 55th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$3,949
Medicare patients
65
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$47,743
FarxigaDapagliflozin Propanediol54$41,915
JardianceEmpagliflozin41$41,154
TrulicityDulaglutide21$31,792
EliquisApixaban23$20,118
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$16,746
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$13,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,062
Breo ElliptaFluticasone/Vilanterol18$12,743
Albuterol Sulfate HfaAlbuterol Sulfate86$3,643
Pregabalin24$2,118
Omeprazole116$1,729
Dexlansoprazole DrDexlansoprazole12$1,623
Atorvastatin Calcium162$1,425
Gabapentin116$1,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$43$58,66165 claims
Novo NordiskOzempic$14$47,74330 claims
Boehringer IngelheimJardiance$126$41,15441 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$279$38,99551 claims
Lilly USA, LLCTrulicity$12$31,79221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,103 family providers in Arkansas.

Other family in Pocahontas

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →